Also categorized in Clinical Research:
Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen DeVos Children’s Hospital
x hide permanently

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

ncbi.nlm.nih.gov

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Oncoimmunology. 2017;6(11):e1358331

Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

Mentions: Antibody